A.V. Kochubeynik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A.V. Kochubeynik has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alla A. Tarasova
“Privolzhsky Research Medical University” of the Ministry of Health of Russia
1 shared publication D.V. Smirnov
Dental Clinic Filatova and Mareev
1 shared publication- Maria Alexandrovna Kvasova
Federal State Budgetary Educational Institution of Higher Education, Privolzhsky Research Medical University, Ministry of Health of the Russian Federation, Nizhniy Novgorod 603005, Russia
1 shared publication - Mikhail Petrovich Kostinov
I.I. Mechnikov Research Institute of Vaccines and Sera; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
1 shared publication O.A. Novozhilova
«Privolzhsky Research Medical University» of the Ministry of Health of the Russian Federation
1 shared publicationT.A. Smirnova
«Privolzhsky Research Medical University» of the Ministry of Health of the Russian Federation
1 shared publication
Latest Publications
- Open Access
- 15 September 2022
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 21 (4) , 119-124
Approaches to Vaccination of Patients with Diabetes Mellitus and Obesity in the Current Epidemiological Situation
Relevance. To date, there is ample evidence that diabetes mellitus (DM) and obesity are predictors of a severe course and adverse outcome of COVID-19. The SARS-CoV-2 virus is known to have deleterious effects on the pancreas, exacerbating insulin resistance The SARS-CoV-2 virus is known to have deleterious effects on the pancreas, exacerbating insulin resistance. Long-term data have been accumulated regarding pneumococcal infection and influenza, both of which are severe in patients with diabetes and obesity. The aim is to analyze scientific publications on the problems of vaccinating patients with diabetes and obesity against SARS-CoV-2, pneumococcal infection, and influenza. Conclusions. Vaccination against COVID-19 in patients with DM and obesity is an effective preventive measure. Experience with vaccination against COVID-19 using the following vaccines: Moderna mRNA-1273, Pfizer BioNTech, BNT162b2, AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience, Sputnik V showed similar safety and efficacy profiles among obese and DM patients and those at risk. Researchers in numerous publications have emphasized the importance of routine vaccination for people living with diabetes amid a pandemic of a new coronavirus infection. Researchers in numerous publications have emphasized the importance of routine vaccination for people living with diabetes in the face of a new coronavirus pandemic. Analysis of the literature reviewed in this review suggests that vaccination against SARS-CoV-2, especially for those at risk, will be an intensive area of research in the coming years and that vaccination against coronavirus infection is likely to be routine for people with diabetes and obesity.
- 15 September 2022
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 21 (4) , 119-124
Open AccessApproaches to Vaccination of Patients with Diabetes Mellitus and Obesity in the Current Epidemiological Situation
Relevance. To date, there is ample evidence that diabetes mellitus (DM) and obesity are predictors of a severe course and adverse outcome of COVID-19. The SARS-CoV-2 virus is known to have deleterious effects on the pancreas, exacerbating insulin resistance The SARS-CoV-2 virus is known to have deleterious effects on the pancreas, exacerbating insulin resistance. Long-term data have been accumulated regarding pneumococcal infection and influenza, both of which are severe in patients with diabetes and obesity. The aim is to analyze scientific publications on the problems of vaccinating patients with diabetes and obesity against SARS-CoV-2, pneumococcal infection, and influenza. Conclusions. Vaccination against COVID-19 in patients with DM and obesity is an effective preventive measure. Experience with vaccination against COVID-19 using the following vaccines: Moderna mRNA-1273, Pfizer BioNTech, BNT162b2, AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience, Sputnik V showed similar safety and efficacy profiles among obese and DM patients and those at risk. Researchers in numerous publications have emphasized the importance of routine vaccination for people living with diabetes amid a pandemic of a new coronavirus infection. Researchers in numerous publications have emphasized the importance of routine vaccination for people living with diabetes in the face of a new coronavirus pandemic. Analysis of the literature reviewed in this review suggests that vaccination against SARS-CoV-2, especially for those at risk, will be an intensive area of research in the coming years and that vaccination against coronavirus infection is likely to be routine for people with diabetes and obesity.
- 1 June 2021
- Published by Stomatology for All - International Dental Review in Stomatology for all / International Dental Review
- No. 2021 2 95
Dental mask of gastroesophageal reflux disease
In clinical practice, there are patients for whom traditional methods of treatment do not allow getting rid of a dental disease. Dental mask of underlying pathology may be a potential cause of this. The aim of the study was to study the features of the clinical course of dental manifestations of gastroesophageal reflux disease. Methods. The study group included 45 patients aged 20 to 50 years with complaints of pathological changes in the oral cavity that did not stop during the last month. The survey included a survey and clinical examination. The GerdQ questionnaire was used to verify gastrointestinal disorders. Results. It was found that 85% of the surveyed complained of a burning sensation behind the breastbone, the ingress of acidic contents into the oral cavity. 100% of the surveyed presented dental complaints. At the same time, the frequency of dental complaints was significantly higher compared to the frequency of complaints of esophageal symptoms. According to the results of the GerdQ questionnaire, the average score among the subjects was 11.0, which corresponds to the presence of gastroesophageal reflux disease. According to the results of the dental examination, 87% of the examined patients had pathological elements on the oral mucosa, and the pathological elements of aphthous and herpetic stomatitis were found significantly more often in patients with an exacerbation of gastroesophageal reflux disease (p<0.05). Desquamative glossitis was detected in 33% of the examined patients, benign migratory glossitis (“geographical” tongue) in 59% of patients, exfoliative cheilitis (dry form) in 70% of patients, angular cheilitis in 23% of patients. The pathology of hard dental tissues was represented by multiple carious lesions in 75% of patients and non-carious lesions in 53% of patients. Conclusions. Diseases of the oral mucosa and non-carious lesions accompany patients with gastrointestinal tract pathology in the form of gastroesophageal reflux disease.
- 1 June 2021
- Published by Stomatology for All - International Dental Review in Stomatology for all / International Dental Review
- No. 2021 2 95
Dental mask of gastroesophageal reflux disease
In clinical practice, there are patients for whom traditional methods of treatment do not allow getting rid of a dental disease. Dental mask of underlying pathology may be a potential cause of this. The aim of the study was to study the features of the clinical course of dental manifestations of gastroesophageal reflux disease. Methods. The study group included 45 patients aged 20 to 50 years with complaints of pathological changes in the oral cavity that did not stop during the last month. The survey included a survey and clinical examination. The GerdQ questionnaire was used to verify gastrointestinal disorders. Results. It was found that 85% of the surveyed complained of a burning sensation behind the breastbone, the ingress of acidic contents into the oral cavity. 100% of the surveyed presented dental complaints. At the same time, the frequency of dental complaints was significantly higher compared to the frequency of complaints of esophageal symptoms. According to the results of the GerdQ questionnaire, the average score among the subjects was 11.0, which corresponds to the presence of gastroesophageal reflux disease. According to the results of the dental examination, 87% of the examined patients had pathological elements on the oral mucosa, and the pathological elements of aphthous and herpetic stomatitis were found significantly more often in patients with an exacerbation of gastroesophageal reflux disease (p<0.05). Desquamative glossitis was detected in 33% of the examined patients, benign migratory glossitis (“geographical” tongue) in 59% of patients, exfoliative cheilitis (dry form) in 70% of patients, angular cheilitis in 23% of patients. The pathology of hard dental tissues was represented by multiple carious lesions in 75% of patients and non-carious lesions in 53% of patients. Conclusions. Diseases of the oral mucosa and non-carious lesions accompany patients with gastrointestinal tract pathology in the form of gastroesophageal reflux disease.